Nightstar Therapeutics plc
Nightstar Therapeutics plc (NITE): 7 pipeline candidates · ~41 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
40.9 months
D/E 0.13 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for Nightstar Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$94.6M
Quarterly Burn
$11.4M
Runway
40.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$353K
| Holder | Shares | Value |
|---|---|---|
| gts securities llc | 9,866 | $332K |
| ubs group ag | 593 | $20K |
| ifp advisors, inc | 30 | $1K |
Frequently asked questions
How many drug candidates are in Nightstar Therapeutics plc's pipeline?
Nightstar Therapeutics plc (NITE) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nightstar Therapeutics plc's lead drug candidate?
Nightstar Therapeutics plc's most advanced tracked candidate is nsr-abca4 (Preclinical) for Stargardt disease.
What is Nightstar Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nightstar Therapeutics plc has approximately 40.9 months of cash runway.
What is Nightstar Therapeutics plc's market capitalization?
Nightstar Therapeutics plc's market capitalization is approximately $1.2B.
Get the full picture on Nightstar Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.